The U.S. FDA granted Qorvo emergency use authorization (EUA) for the Qorvo Omnia™ SARS-CoV-2 Antigen Test. Qorvo was also awarded a $24.4 million contract with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADxSM) initiative.
